{"id":"jak1","name":"JAK1","symbol":"JAK1","route":"/targets/jak1/","asOf":"2026-09-22","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6190","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162434","uniprot":"https://www.uniprot.org/uniprotkb/P23458/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P23458","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2835","open-targets":"https://platform.opentargets.org/target/ENSG00000162434","civic":"https://civicdb.org/genes/3716/summary","oncokb":"https://www.oncokb.org/gene/JAK1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=JAK1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=JAK1","depmap":"https://depmap.org/portal/gene/JAK1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000162434-JAK1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3716","omim":"https://www.omim.org/entry/147795"}],"products":[{"id":"golidocitinib","name":"Golidocitinib","status":"approved","modality":"Oral selective JAK1 inhibitor","route":"/drugs/golidocitinib/"},{"id":"momelotinib","name":"Momelotinib","status":"approved","modality":"Small-molecule JAK1/JAK2/ACVR1 inhibitor","route":"/drugs/momelotinib/"},{"id":"ruxolitinib","name":"Ruxolitinib","status":"approved","modality":"Small-molecule JAK1/JAK2 inhibitor","route":"/drugs/ruxolitinib/"}],"trials":[{"id":"manifest-2","name":"MANIFEST-2","nct":"NCT04603495","phase":"3","status":"mixed"},{"id":"momentum","name":"MOMENTUM","nct":"NCT04173494","phase":"3","status":"positive"},{"id":"response-2","name":"RESPONSE-2","nct":"NCT02038036","phase":"3","status":"positive"},{"id":"response","name":"RESPONSE","nct":"NCT01243944","phase":"3","status":"positive"},{"id":"comfort-i","name":"COMFORT-I","nct":"NCT00952289","phase":"3","status":"positive"},{"id":"comfort-ii","name":"COMFORT-II","nct":"NCT00934544","phase":"3","status":"positive"},{"id":"nct07234162","name":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","nct":"NCT07234162","phase":"3","status":"recruiting"},{"id":"nct04562389","name":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","nct":"NCT04562389","phase":"3","status":"active"},{"id":"nct04543279","name":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia","nct":"NCT04543279","phase":"2"},{"id":"majic-pv","name":"MAJIC-PV","phase":"2","status":"positive"},{"id":"majic-et","name":"MAJIC-ET","phase":"2","status":"negative"},{"id":"aall1521","name":"AALL1521","nct":"NCT02723994","phase":"2","status":"completed"},{"id":"nct02955940","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","nct":"NCT02955940","phase":"2","status":"active"},{"id":"nct06198907","name":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)","nct":"NCT06198907","phase":"2","status":"planned"},{"id":"nct07110103","name":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","nct":"NCT07110103","phase":"2","status":"recruiting"},{"id":"nct03669965","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","nct":"NCT03669965","phase":"2","status":"active"},{"id":"nct04509700","name":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","nct":"NCT04509700","phase":"2","status":"active"},{"id":"nct04817007","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","nct":"NCT04817007","phase":"1/2","status":"active"},{"id":"nct07496229","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","nct":"NCT07496229","phase":"1/2","status":"recruiting"},{"id":"nct07219576","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","nct":"NCT07219576","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["dizal","gsk","incyte","novartis"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}